Sharon Shacham - Feb 28, 2022 Form 4 Insider Report for Karyopharm Therapeutics Inc. (KPTI)

Role: Chief Scientific Officer
Signature: /s/ Nancy Smith as Attorney-in-Fact for Sharon Shacham
Stock symbol: KPTI
Transactions as of: Feb 28, 2022
Transactions value $: -$127,477
Form type: 4
Date filed: 3/2/2022, 02:20 PM
Previous filing: Feb 22, 2022
Next filing: Mar 31, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KPTI	Common Stock	Sale	-$63.7K	-6.23K	-0.69%	$10.24^*	898K	Feb 28, 2022	Direct	F1, F2
transaction	KPTI	Common Stock	Award	$0	+21K	+3%	$0.00	720K	Feb 28, 2022	By Spouse	F3
transaction	KPTI	Common Stock	Sale	-$63.7K	-6.23K	-0.86%	$10.24^*	714K	Feb 28, 2022	By Spouse	F2, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KPTI	Stock Option (right to buy)	Award	$0	+27K		$0.00	27K	Feb 28, 2022	Common Stock	27K	$10.33	By Spouse	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.
F2	Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $10.24 to $10.35, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3	Represents the award of restricted stock units ("RSUs") to the spouse of the reporting person pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 28, 2023.
F4	This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the spouse of the reporting person.
F5	This option was granted to the spouse of the reporting person on February 28, 2022 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 28, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter.